Q-omics provides the consensus-scored ELOVL6 profile across patient tissues and cancer cell-line models. ELOVL6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ELOVL6 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, ELOVL6 RNA expression shows 19,751 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LUAD, and UVM as cancer lineages where ELOVL6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOVL6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOVL6 survival associations across molecular data types. ELOVL6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOVL6 RNA expression–survival associations across cancer types. High ELOVL6 expression shows unfavorable associations in HNSC, KICH, LUAD, UVM and SARC, but favorable associations in COAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ELOVL6 RNA expression.
This table summarizes ELOVL6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ELOVL6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOVL6 shows lower tumor expression in COAD and higher tumor expression in LUAD, BLCA, THCA, LUSC and UCEC. The LUAD box plot shows higher ELOVL6 RNA expression in tumor versus normal tissue (log2 FC = +1.533, t-test p < 0.001).
This table shows molecular features associated with ELOVL6 in patient tissues and cancer cell lines. In patient samples, ELOVL6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ELOVL6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
